INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
ORDER A TEST Log In Contact Us
Back TO GENOMIC PROFILING

xMPortfolio of Minimal Residual Disease & Monitoring

Our portfolio of tumor-naive and tumor-informed minimal residual disease (MRD) and monitoring assays provides physicians with valuable patient insights to individualize treatment plans.

xM is a finely tuned MRD assay that delivers rapid results from one blood draw to help detect residual disease or recurrence in colorectal cancer.

xM (NeXT Personal® Dx)* is an ultra sensitive, whole genome assay that enables detection of ctDNA at very low levels to monitor residual disease and recurrence and IO treatment response monitoring.

*Test by Personalis

LEARN MORE

xM is a tumor-naive, finely tuned assay for colorectal cancer

ASSAY DESIGN

xM was developed using Tempus’ multimodal database and advanced machine learning algorithms to help accurately detect and classify tumor fragments from non-tumor fragments.

Tumor-naive approach

xM is a blood-based assay that can be seamlessly integrated into a patient’s routine blood draw schedule, minimizing the burden to clinical practices.

Results

Binary ctDNA status call (detected/not detected)

image description

xM (NeXT Personal® Dx) is a tumor-informed, ultra-sensitive whole genome assay for solid tumors

ASSAY DESIGN

xM (NeXT Personal® Dx) is an ultra-sensitive personalized MRD assay, capable of detecting molecular markers at concentrations as low as 1.67 parts per million (PPM)1. It utilizes whole genome sequencing to identify up to 1800 somatic variants, filtering out confounding factors such as CHIP and germline variants through a tumor normal matched approach.

Tumor-informed approach

xM (NeXT Personal® Dx) utilizes a tumor-informed methodology and provides a personalized assessment of residual disease based on information specific to the patient’s tumor DNA.

results

Binary ctDNA status call (detected/not detected) and quantitative results

Detection of ctDNA may function as an early indicator for recurrent malignancy, prior to being seen on radiographic scans.

xM CLINICAL PERFORMANCE IN COLORECTAL CANCER 2

From a subset analysis from the GALAXY study in CIRCULATE-Japan, xM results predict disease-free survival (DFS) nearly 5 times superior to standard of care carcinoembryonic antigen (CEA).

image description

xM (NeXT Personal® Dx) CLINICAL PERFORMANCE IN NSCLC 3

As observed in a study in early stage NSCLC over a 5 year period, 85% of patients who recurred had ctDNA detected, with a median lead time of ~6 months ahead of clinical relapse.*

image description

xM (NEXT PERSONAL® DX) CLINICAL PERFORMANCE IN BREAST CANCER 4

As observed in a study in early stage breast cancer over a 6 year period, >99% of patients who recurred had ctDNA detected with a median lead time of ~15 months ahead of clinical relapse.*

image description

xM (NEXT PERSONAL® DX) CLINICAL PERFORMANCE IN IO MONITORING 5

Patients with metastatic disease in a pan-cancer cohort receiving IO treatment who saw a molecular response (≥30% decrease in ctDNA by cycle 3) had an overall survival that was more than double that of those without a molecular response.

image description

Improving your workflows

Tempus offers a variety of options to customize MRD testing for patients.

ORDERING FLEXIBILITY

Place a single MRD order or a series of longitudinal orders, based on a cadence you determine is medically necessary.

image description

MOBILE PHLEBOTOMY

We want to make blood draw services as convenient as possible for your patients who are unable to come into typical clinical/hospital settings.

To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.

image description

TEMPUS HUB

Order and view results through our AI-enabled online platform. Paper requisition and EHR ordering are also available.

Access Tempus Hub
image description

Resources

view all RESOURCES
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: Colorectal Cancer Data

    Read more
  • UPCOMING WEBINAR:

    2023 ESMO Congress: NSCLC Data

    Read more
  • UPCOMING WEBINAR:

    2024 ESMO Congress: NSCLC Data

    Read more
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: Breast Cancer Data

    Read more
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: IO Monitoring Data

    Read more
Financial Assistance

We help provide access to our tests for all patients in financial need.

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.
  1. Northcott J, Bartha G, Harris J, et al. Analytical validation of NeXT Personal ®, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget. 2024;15:200-218.
  2. Nakamura Y, Kaneva K, Lo C, et al. Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago Illinois.
  3. Black JRM, et al. An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Ann Oncol. 2023;34(Suppl):S1294-S1294.
  4. Garcia-Murillas I, et al. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in early breast cancer patients. Presented at: ASCO Annual Meeting; June 2, 2024; Chicago, IL.
  5. Based on a study involving a cohort of randomly selected metastatic patients from 18 different cancer types, who received 1-3 successive lines of ICIs in the context of phase 1 clinical trials. Toledo R, et al. Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. Presented at: ASCO Annual Meeting; June 4, 2024; Chicago, IL.

*Data listed is longitudinal data. Longitudinal data encompasses landmark data and refers to a minimum of one MRD test performed post-surgery.

This is data-driven precision medicine

Stay up to date on important product information and learn more about ordering.